Genes involved in 3′-splice site recognition during mRNA splicing constitute an emerging class of oncogenes. SF3B1 is the most frequently mutated splicing factor in cancer, and SF3B1 mutants corrupt branchpoint recognition leading to usage of cryptic 3′-splice sites and subsequent aberrant junctions. For a comprehensive determination of alterations leading to this splicing pattern, we performed a pan-TCGA screening for SF3B1-specific aberrant acceptor usage. While the most of aberrant 3′-splice patterns were explained by SF3B1 mutations, we also detected nine SF3B1 wild-type tumors (including five lung adenocarcinomas). Genomic profile analysis of these tumors identified somatic mutations combined with loss-of-heterozygosity in the splicing factor SUGP1 in five of these cases. Modeling of SUGP1 loss and mutations in cell lines showed that both alterations induced mutant-SF3B1-like aberrant splicing. Our study provides definitive evidence that genetic alterations of SUGP1 genocopy SF3B1 mutations in lung adenocarcinoma and other cancers.
Large-scale genomics studies have identified recurrent somatic mutations in genes encoding components of the pre-messenger RNA splicing machinery (spliceosome) in a variety of human malignancies . The spliceosome is a dynamic complex containing five snRNAs (U1, U2, U4, U5, and U6) and >150 proteins that orchestrates the accurate intron recognition, excision, and exons ligation to form mature mRNA . Catalog of splicing factors with frequent and recurrent somatic mutations in tumors include SF3B1, U2AF1, and SRSF2 with heterozygous missense mutations and ZRSR2 with loss of function mutations [3,4,5,6,7]. Mutations in these genes are mutually exclusive and present in up to half of myelodysplasia [3, 4], in chronic lymphocytic leukemia [7, 8] and in a significant number of solid tumors, including uveal melanoma (UM) [9,10,11], lung adenocarcinoma , and other malignancies [13, 14]. Cancer mutations of U1 spliceosomal small nuclear RNA (snRNA RNU1) were recently found in about 50% of the SHH medulloblastoma subtype and extremely rare in other types of tumors . Recurrent mutations were reported in other splicing genes, including PHF5A, RBM10, and FUBP1, putatively implicated in cancer .
All cancer splicing factors are involved in the earliest stage of spliceosome assembly (spliceosome E and A complexes), where RNA and protein components work together to identify the 5′ splice site (ss), the 3′ss and the branchpoint region, with intervening polypyrimidine tract of nascent pre-mRNA . Exact structural basis and order of early spliceosome assembly events remain partially understood and cancer splice mutations may contribute in identifying key genes help leading investigation of splicing machinery and indicate functional sites of proteins .
SF3B1, a core subunit of U2 component, is critical for branchpoint recognition and for the early stages of spliceosome assembly , and the most frequently mutated splicing gene in cancers [16, 19]. A key function of SF3B1 is to stabilize a duplex between the U2 snRNA and a consensus branchpoint (BP) sequence. Missense mutations found in SF3B1 map to the surface of the HEAT-repeat domains (H3–H6) in the region that interacts with the intron between the BP and 3′ss with the hotspots at codon positions R625, K666, and K700 . These mutations results in usage of cryptic BP and cryptic 3′ss typically located 10–30 nts (nucleotides) upstream of the canonical 3′ss [5, 6, 21]. Beside hotspots, other residues in H3–H6 were associated to aberrant splicing and all of them are predicted to be spatially close to one another [8, 20].
Recently, Zhang et al. demonstrated that cancer-associated mutations of SF3B1 mainly disrupt SF3B1 interaction with SUGP1 during BP recognition and that the loss of this interaction solely accounts for the splicing errors caused by SF3B1 mutations .
We started from a large-scale analysis of the TCGA series of 3′ss splicing aberrations associated with SF3B1 mutations, questioning if all aberrant pattern has a corresponding SF3B1 mutation. We detected tumors with an aberrant splicing pattern, which were wild-type for SF3B1, and found that these tumors were recurrently mutated for SUGP1. We further demonstrated that SUPG1 alterations mimic the 3′ss aberration pattern found in the SF3B1-mutant context.
Results and discussion
Large-scale in silico screening for SF3B1 mut splice pattern in tumors
For a comprehensive view of pathogenic mutations inducing usage of cryptic 3′ss as observed in a SF3B1-mutant context (we will denote by SF3B1mut all SF3B1 mutations that lead to aberrant 3′ss usage), we used a Sequence Bloom Tree (SBT) [23, 24] constructed from RNA-seq data for a total of 11,350 different samples and 33 tumor types from TCGA (Supplementary Fig. S1). SBT is an indexing structure developed for querying large databases for short-read sequences. It is a fast and highly sensitive approach without false negative calls. We tested occurrence of 1443 aberrant junctions previously associated with SF3B1mut in two independent analyses [5, 6]. The SBT score represents the number of these junctions found at least once in raw RNA-seq data (fastq) and characterizes burden of SF3B1mut associated junctions in a tumor.
After adjustment for RNA-seq coverage, the 138 top SBT-score cases were selected following the cutoff determined by the lowest SBT score of a validated SF3B1A633V case (Supplementary Table 1, Fig. 1a). These high SBT-score cases were thoroughly verified for SF3B1 mutations in exome and RNA sequencing data using IGV .
We detected six additional SF3B1-mutated cases not previously reported . Six cases with marginal variant allele frequency (VAF) at a subclonal level (RNA-seq VAF~0.1) displayed high SBT scores. Cases showing no read supporting an SF3B1 hotspot mutation in the RNA-seq data had consistently low SBT scores. SF3B1 mutations at positions 742, 741, and 633 represented the lower limit of SBT scores observed in tumors mutated for SF3B1 in the 500–800aa region. Two UCEC cases displayed identical mutations p.R549C and elevated SBT scores, possibly defining the N-terminal limit (domain H1) of functional sites for which mutations could induce 3′ss aberrations.
To confirm the aberrant splicing pattern, we analyzed 3′ss usage in 456 cases, including cases identified by a high SBT score (n = 128) and a selection of control cases using the STAR software (“Materials and methods”, Supplementary Table 1). We calculated quantiles of canonical and aberrant junctions, denoted CQ and AQ, respectively. The set of 366 3′ss aberrant junctions was selected from ubiquitously-expressed exons (CQ ≥ 0.3 in 95% cases) in an unsupervised manner: the junction was included if aberrant and corresponding canonical junction were expressed (AQ ≥ 0.4 and CQ ≥ 0.5) and splicing index SI ≥ 0.15 at least in one sample. Principal component analysis (PCA) of cryptic 3′ss usage characterized by SI showed the main source of variation to be SF3B1 mutations and the phenotype is characterized by increased expression of cryptic 3′ss (Fig. 1b, Supplementary Fig. S2a). We considered 83 cases, including 74 SF3B1-mutated cases, to display an aberrant splice pattern, on the ground that their PC1 (principal component 1) scores exceeded the median + 3·MAD (Median Absolute Deviations) cutoff (Supplementary Table 1). This result represents the exhaustive list of the TCGA cases with 3′ss aberrations characteristic to SF3B1 hotspots mutations (Supplementary Fig. S2b).
SUGP1 alterations associated with a SF3B1 mut splice pattern in tumors
Nine tumors showing high levels of the 3′ss pattern but not mutated in SF3B1 (hereafter named SF3B1-like) were detected, including lung adenocarcinomas (LUAD, five cases), hepatocellular carcinoma (LIHC, one case), mesothelioma (MESO, one case), acute myeloid leukemia (LAML, one case), and skin melanoma (SKCM, one case).
Mutational analysis of RNA processing genes (GO:0006396) of the nine SF3B1-like cases revealed mutations in SUGP1 (also known as Splicing Factor 4 or SF4) as the only common event for five cases: four missense (p.L515P, p.G519V, p.R625T, and p.P636L) and one stop-gain (p.G26*) mutations. Further analyses using SNP-arrays revealed loss of heterozygosity (LOH) of the SUGP1 locus in all five cases and VAF in RNA-seq data was consistent with loss of the wild-type allele (Supplementary Table 1). Given that only eight cases out of the entire TCGA series carried SUGP1 variants with RNA-seq VAF > 0.3 and LOH, enrichment of SUGP1 variant + LOH (SUGP1LOH/mut) within cases with a SF3B1-like phenotype is highly significant (p < 10–8, Fisher’s exact test adjusted for multiple testing). Worth noting that beside five SUGP1 mutations + LOH associated with an SF3B1-like phenotype, there are three missense mutations + LOH and more than 50 missense and deleterious mutations in heterozygous state found in the TCGA (Fig. 1c). We reviewed the splicing pattern found in the corresponding tumors and confirmed the absence of any enrichment in 3′ss aberrations (Supplementary Fig. S3a).
We further mined the four SF3B1-like cases associated with neither SF3B1 nor SUGP1 mutation. Normalized SUGP1 expression levels in two cases (one LUAD and one LIHC) were the lowest in the corresponding cohorts having z-scores < −5 and expression at the lower limit for expressed genes (Supplementary Fig. S4bc). Interestingly, we also observed LOH in the SUGP1 locus for these two cases. The remaining two cases (one LAML and one SKCM) associated with the SF3B1-like splice pattern were not found altered for SUGP1. Of note, the LAML case with a strong SF3B1-like pattern harbored a U2AF1S34Y hotspot mutation, which is not likely to be causal, as 20 other U2AF1S34Y/F cases showed no evidence of such pattern and as U2AF1 mutations are known to drive an alternative exon usage [26, 27].
SUGP1LOH/mut display aberrant 3′ splicing and cryptic branchpoint recognition
The splicing factor SUGP1 has two SURP and one G-patch domains and was shown to be dispensable for the assembly of a functional splicing complex [28, 29]. SUGP1 interacts with SF3B1 and SF3B1 hotspot mutations disrupt this interaction. Moreover, aberrant recognition of BPs and cryptic 3′ss was shown for SUGP1 KD and for double mutations in G-patch domain of SUGP1 . Here we detected five mutations in SUGP1 associated with LOH and SF3B1-like splicing pattern in cancers (Fig. 1c). Interestingly, missense mutations do not target any known interaction domain of SUGP1 and are located before and after its G-patch domain.
We assessed the impact of SUGP1 alterations found in cancers, including LOH and mutations, on splicing. Using HEK293T cells (wild-type for both SUGP1 and SF3B1), we performed siRNA-mediated SUGP1 knockdown and overexpression of the SUGP1 L515P, R625T, and P636L mutants. As readout, we assessed the splicing ratio, which is the ratio of aberrant to canonical junction expression, in three SF3B1mut–sensitive junctions: DPH5, DLST and ARMC9, as previously reported . The knockdown of SUGP1 using four different siRNAs consistently and significantly induced the SF3B1mut-aberrant pattern (p < 0.05 to <0.0005, depending on the siRNA and junctions; Fig. 1d). Transiently overexpressed SUGP1 mutants induced either significant but modest effects on splicing (L515P and P636L) or no significant effect (R625T) (Fig. 1e; Supplementary Fig. S3b), arguing against strong dominant-negative properties of these mutants.
The p.G26* stop mutation, located at the very beginning of the gene, was well expressed in the tumor, suggesting an alternative initiation of translation bypassing the Nonsense-Mediated mRNA Decay (NMD) in this sample (Supplementary Fig. S4b). Indeed, we demonstrated by expressing SUGP1 cDNA carrying this G26* mutation the existence of this alternative initiation coding an N-terminal truncated protein (Supplementary Fig. S4c).
In an SF3B1-mutant context, the U2 complex has a preferential recognition for the cryptic branchpoint BP’. To determine whether SUGP1 loss affects U2 recognition of the BP in a similar manner, we performed a splice-reporter assay with SF3B1mut-sensitive junctions (ENOSF1 and TMEM14C) containing adenine mutants inactivating either the canonical or cryptic BPs . Our results showed that mutants disrupting the BP’ abolish the splice aberration induced by siRNA-mediated SUGP1 knockdown (Fig. 1f). This finding demonstrates that SUGP1 is critical for correct recognition of the BP by the U2 complex, and that its loss leads to aberrant 3′ss usage similar to SF3B1mut.
Common splice pattern of SUGP1 and SF3B1 cases in LUAD
We questioned overall impact of cancer SUGP1 alterations (SUGP1alt) on splicing in comparison to SF3B1mut, taking advantage of LUAD cohort containing five SUGP1 (four SUGP1LOH/Mut and one case with the lowest SUGP1 expression) and six SF3B1mut cases; cases without mutations in splicing genes were taken as controls (400 LUAD cases). We developed a bioinformatics protocol to test similarity of the global aberrant splicing patterns, which takes into account transcriptional heterogeneity of lung adenocarcinoma, significant variation in RNA-seq coverage and small sample sizes of SUGP1alt and SF3B1mut groups (“Materials and methods”). First, we applied Wilcoxon nonparametric rank test to compare SI in SUGP1alt vs. Controls, SF3B1mut vs. Controls and SUGP1alt vs. SF3B1mut for each type of splice aberration. P value distribution in both SUGP1alt vs. Controls and SF3B1mut vs. Controls comparisons showed significant enrichment in low p values only for the proximal 3′ss (p value < 10−11, Fisher test; Fig. 2a, Supplementary Figs. S5–S8). SUGP1alt vs. SF3B1mut did not show any enrichment in low p values for any type of splice aberration considered, evidencing no differences beyond background (Fig. 2a, Supplementary Figs. S5–S8).
Second, we applied PCA for each comparison in each type of splice aberrations using corresponding junctions with Wilcoxon test p values < 0.05 (not corrected for multiple testing), to test if there is a major (with proportion of explained variance >5%) principal component (PC) that separates SUGP1alt, SF3B1mut, and the Control group. If such PCs are found, aberrant junctions with high loadings (correlated with PC) are picked up as differentially expressed aberrant junctions.
Comparison of proximal 3′ss cryptic junctions revealed PCs associated to SUGP1alt and SF3B1mut. Moreover, (i) the junctions correlated with PCs (211 and 179, respectively) were largely shared (110 in common, p < 10–10); and (ii) SUGP1alt were not found separated from SF3B1mut in major PCs subspace: at least one case with SUGP1alt has SF3B1mut as a nearest neighbor and vice versa (Fig. 2b). Figure 2c shows a refined analysis of 238 (shared and definitively not shared, see “Materials and methods”) aberrant junctions and their distribution around exon start (−50 to 50nts selection). Shared junctions constitute 85% of aberrant AG’ at 10–30nts distance upstream exon start, evidencing that SUGP1alt and SF3B1mut have a common set of sensitive splice sites (Fig. 2c). Consequently, the nucleotide composition of aberrant acceptors in SF3B1mut and SUGP1alt as analyzed by Weblogo showed no difference (Supplementary Fig. S9a).
Following the same approach, we explored 5′ss proximal, 3′ and 5′ss distant aberrations and alternative exon usage. No major PC separating SUGP1alt and SF3B1mut from the Control group was found in any of comparisons (Supplementary Figs. S5–S8). Even though the differences between SF3B1mut and SUGP1alt could be noticed, they are not specific to SF3B1mut and SUGP1alt, because the aberrations are shared by some (or many) control cases, which is further illustrated by the heatmap (Fig. 2d). Hierarchical clustering on the aberrant junctions with high loadings demonstrates background level in cryptic 5′ss and aberrant exon usage in both SUGP1alt and SF3B1mut groups. Conversely, alternative junctions using cryptic 3′ss displayed overexpression in both SUGP1alt and SF3B1mut groups as compared with wild-type tumors (Fig. 2d). Furthermore, cryptic 3′ss were mostly found 10–30nts upstream to canonical 3′ss in both groups, with a strong concurrence of sensitive junctions (Fig. 2c). Therefore, we conclude that we observed no difference in aberrant splicing pattern between SF3B1mut and SUGP1alt in the LUAD cohort.
Here we applied supervised PCA protocol that helps revealing relevant junctions even with moderate significance, eliminating effect of confounding factors. The condition for PC selection to separate Control and SF3B1mut or SUGP1alt groups accounts for transcriptional heterogeneity and follows the assumption that aberrant junctions show up almost exclusively in the groups with alteration in a splicing factor (if many controls behave similar to mutated cases, the feature is not specific to the mutated cases even though the test shows significant differences (Supplementary Figs. S5–S8).
Exploring the possible common consequences of SF3B1mut or SUGP1alt in oncogenesis, we found three common altered genes belonging to the cancer gene census (https://cancer.sanger.ac.uk/census) (Supplementary Fig. S9b). Among previously described targets PPP2R5A  was found in both contexts, whereas BRD9  was only targeted in a SF3B1mut context. Only a minority (47 out of 110) of aberrant junctions led to out-of-frame transcripts when 2/3 were expected, suggesting that the majority of out-of-frame junctions used in a SF3B1mut or SUGP1alt context are not detected, probably because degraded by NMD process (Supplementary Fig. S9с).
SF3B1mut-splice pattern in SUGP1 alt cellular models
To evaluate if SUGP1 alterations are indeed the causes of the abnormal splicing pattern, we set up two experimental models using HEK293T and isogenic HAP1 cell lines and analyzed their RNA-seq data.
Splicing patterns in HEK293T cells transiently depleted for SUGP1 (SUGP1KD) or over-expressing SF3B1K700E were compared with siControl and SF3B1WT overexpression, using relative shift in splice indexes (∆SImax) (“Materials and methods”). We selected junctions in a semi-unsupervised way and visualized data using 2D plots showing relative change in splice indexes SUGP1KD vs. SF3B1K700E for each junction (Fig. 3a). This showed coherent changes in SUGP1KD and SF3B1K700E splice profiles only within 3′ss aberrations (Pearson’s correlation r = 0.6, p value < 10–10; two illustrative examples are shown in Fig. 3b). Aberrations at 5′ss as well as alternative exon usage showed single outlying junctions with high ∆SImax and no evidence of being systematically affected in either of experimental groups (Supplementary Figs. S10–S13). The subset of aberrant junctions with ∆SImax > 1 in either SUGP1KD or SF3B1K700E (74 and 49 junctions, respectively, 97 in total) showed coherent overexpression with increased usage of cryptic 3′ss located 10–30nts upstream of the canonical 3′ss (Fig. 3c, d). It is worth noting that even though maximum is least robust statistic, ∆SImax shows amplitude of changes in the “best” reacting replicate and is instrumental in exploratory analysis of marginally small experimental groups.
To recapitulate the homozygous state of SUGP1 mutants found in tumors, we generated a haploid cell model harboring the SUGP1P636L mutation (HAP1SUGP1-P636L) by CRISPR/cas9 editing. HAP1SUGP1-P636L cells displayed splice aberrations consistent with the SF3B1mut pattern, and mainly characterized by the usage of cryptic 3′ss at 10–25nts upstream the canonical 3′ss (Fig. 3e, Supplementary Fig. S14).
The assessment of DPH5 aberrant junction expression confirmed the induction of the SF3B1mut–splice pattern in HAP1SUGP1-P636L as compared to HAP1 (Fig. 3c). Strikingly, siRNA-knockdown of the SUGP1P636L further increased the aberrant splice index, implying that SUGP1 mutations lead to a partial loss of function (hypomorphic mutations) accentuated by the mutant knockdown (Fig. 3f). These experiments elucidated the respective role of reduced SUGP1 expression by LOH and of hypomorphic mutations found combined in tumors and demonstrated that SUGP1 phenocopies SF3B1 3′ss aberration at the whole transcriptome level.
Here we introduced a new splice factor recurrently mutated in cancers. Starting from the pan-cancer SF3B1-like 3′ss aberration pattern, we explained almost all cases either by new SF3B1 mutations outside of the known hotspots or by SUGP1 alterations. Only two SF3B1-like cases were not associated with either SF3B1 or SUGP1 alterations and only one of these cases (LAML) had a strong alteration pattern, whereas the SKCM case associated with weak 3′ss aberration pattern could be false positive. Furthermore, we previously described one SF3B1 wild-type UVM case with such 3′ss pattern, and no SUGP1 alteration were found retrospectively. Thus, it is likely that other genetic alterations remain to be found in cancers, leading to 3′ss altered usage. Despite the extreme rarity of such cases, it will be important to elucidate these remaining cases as they could unravel important new players in 3′ss selection.
Our work not only confirms the results of Zhang et al.  and Liu et al. , but also extends them by demonstrating no detectable difference between SF3B1mut and SUGP1alt splice aberration patterns in cancers and in cellular models. We strengthen that only mutations with LOH are associated with 3′ss aberrant phenotype. In addition, we detected two cases with outlying low expression of SUGP1 (also with LOH), explaining two more cases with 3′ss aberrations. We further validated the dysfunction of SUGP1 mutants by RNA-seq analyses of original isogenic models. Our data are in line with the previously suggested mechanism of the disruption of SUGP1/SF3B1 interaction induced by the pathologic mutants. We also provide direct experimental evidences supporting that the depletion of SUGP1 together with expression of a SUGP1 mutation induce the SF3B1mut-splice pattern in a cumulative manner, which fits the co-occurrence of LOH and SUGP1 mutations in tumors. In absence of fully inactivated SUGP1 animal or cellular models, or tumors reported so far, it is still unclear whether SUGP1 is an essential gene. However, large depletion of SUGP1 expression, often combined with SUPG1 hypomorphic variants, are not only tolerated by tumor cells but likely to be associated with the oncogenic process.
Materials and methods
Large-scale in silico screening for SF3B1 mut splice aberrations in tumors
SBTs were generated based on the RNA-seq fastq files for all samples of the 33 tumor types of the TCGA [23, 24]. The list of 1443 aberrant splice junctions previously reported in SF3B1mut tumors was generated (40nts sequences centered on the aberrant 3′ splice site) [5, 6, 21]. Using the SBT structure and the Seven Bridges cloud platform [23, 24], we obtained SBT scores, corresponding to the occurrence of junctions for each tumor sample: each junction was scored as 1 if found and 0 if not (two mismatches were allowed).
A linear model (SBT score ~RNA-seq bam size in gigabytes [GB]) was fit using R custom script excluding top 1% of SBT scores. Fitted values were obtained for all samples and the residuals were taken to characterize adjusted SBT score of the tumors.
SF3B1 mutations in the 138 cases with the highest SBT scores (cutoff determined by the lowest SBT score of a validated SF3B1A633V case) were checked using preprocessed vcf files from the TCGA, samtools mpileup  in the wild-type cases, followed by manual inspection using IGV; only expressed SF3B1 mutations (detectable in RNA-seq) were taken into account and only the 500–800aa region was considered for SF3B1 mutations.
RNA-seq preprocessing and selection of junctions
Analysis of splice junctions was performed using STAR 2.5.0  with default parameters (using—quandMode GeneCounts, mapped on hg19 or hg38). Junctions were extracted, annotated as canonical or aberrant based on the gene annotation (NCBI Refseq from UCSC) and normalized using quantiles of canonical junctions (CQ and AQ denote quantiles of canonical and aberrant junctions). Aberrant junctions were paired with the corresponding canonical junctions and annotated as half-canonical 3′ proximal (aberrant junctions ≤100nts to canonical 3′), half-canonical 5′ proximal (aberrant junctions ≤100nts to canonical 5′), half-canonical distant (aberrant junctions >100nts to canonical 3′ or 5′) and aberrant exon (2 exons from the same gene with not annotated junction); junctions with 2 noncanonical ends and chimeric junctions (connecting two different genes) were excluded. Splicing index (SI = N aberrant split reads/(N aberrant + N canonical split reads)) was calculated. For unsupervised aberrant junction selection, we required at least one case from the series to satisfy: (i) SI ≥ SImin; (ii) aberrant junction to be expressed AQ ≥ AQmin; and (iii) corresponding canonical junction to be expressed CQ ≥ CQmin, where SImin, AQmin, and CQmin are minimal values defined for each series. Junction selection was performed using custom R-script.
Pan-TCGA analysis of cryptic 3′ splice junctions
RNA-seq data were preprocessed as described above (mapping on the Seven Bridges cloud platform, hg38) on 456 selected cases, including 128 out of the 138 cases with high SBT scores (RNA-seq coverage in ten cases was below the lower limit of 3GB for junction analysis, Supplementary Table 1); and 328 cases with low SBT scores, including 182 cases carrying splice mutations (91 SF3B1, 49 U2AF1, and 48 SRSF2, whatever the position of the mutation—some tumors harboring more than one mutation) and 146 control tumors wild-type for splicing genes from the 21 tumor types having at least one case with high SBT score. Cases with mutations in U2AF1, SRSF2 and out of hotspot region SF3B1 were extracted from the vcf files from the TCGA. Proximal 3′ junctions 5–50nts upstream to canonical 3′ss were selected for further analysis if at least one case in the series satisfy the condition SI ≥ 0.15, AQ ≥ 0.4, and CQ ≥ 0.5 (n = 975 junctions). To overcome tissue heterogeneity, we also required that the corresponding canonical junctions show at least marginal expression (CQ ≥ 0.3) in 95% of cases. PCA was applied on the set of 336 junctions characterized by SI (R v3.6.1).
Screening for SUGP1 mutations in the TCGA
SUGP1 mutations were extracted from vcf files from the TCGA (exome VAF > 0.1, RNA-seq VAF > 0.3 for missense mutations). Allelic status was determined from SNP-arrays processed by the GAP method . Samtools mpileup  was applied to check cases with high SBT scores, followed by manual inspection using IGV of exome and RNA-seq.
Analysis of junctions of TCGA LUAD
RNA-seq data for LUAD series (514 cases) were preprocessed as described above (hg19). Cases with the lowest RNA-seq coverage (n = 75) and cases with U2AF1 34F/Y mutations (n = 8) or RBM10 inactivation (n = 20) were excluded. Minimal requirements for an aberrant junction to be included were: SI ≥ 0.1, AQ ≥ 0.4, and CQ ≥ 0.5 in at least one case. Half-canonical 3′ proximal (n = 5357), half-canonical 5′ proximal (n = 1788), half-canonical distant (n = 6303) and aberrant exon (n = 2501) junctions in SUGP1 altered (n = 5, including mutated and low expression cases), SF3B1 mutated (n = 6) and control (n = 400) groups were compared using the bioinformatics protocol described below.
We developed a bioinformatics protocol to test similarity of the global aberrant splicing patterns in SF3B1mut and SUGP1alt tumors relative to Controls: (i) we applied a Wilcoxon nonparametric rank test to compare SI in SUGP1alt vs. Controls and SF3B1mut vs. Controls independently, and selected differentially expressed aberrant junctions (p value < 0.05, not corrected for multiple testing); (ii) We applied PCA and selected major (with proportion of explained variance >5%) PCs associated with the SF3B1mut or SUGP1alt groups. We consider PC to be associated to SF3B1mut or SUGP1alt groups when the PC scores separate mutated cases from the Control group; (iii) If such PCs are found, we considered the junctions correlated with these PCs (Pearson correlation >0.2 or PC loadings >0.05) to be specific to the mutated splicing factor. This protocol was applied to each type of aberrant junctions; intron retention was not considered because of not sufficient RNA-seq coverage in LUAD.
To test significance, the number of shared junctions was compared with the random expected value (obtained using resampling simulation). To refine the set of shared junctions, we re-evaluated the estimation of aberrant expression in the union of SF3B1mut and SUGP1alt specific aberrant junctions using maximal SI (SImax) in the groups. We consider a junction (i) as shared if SImax > SIQ95 (95 quantile of the Controls) for both groups; (ii) as definitively not shared if one SImax > SIQ95 and the other SImax < SIQ75; (iii) as not determined otherwise. Not determined junctions were excluded from further comparison.
RNA sequencing of HEK293 and HAP1 cell lines
The total RNA was isolated from cells using a NucleoSpin Kit (Macherey-Nagel). cDNA synthesis was conducted with MuLV Reverse Transcriptase in accordance with the manufacturers’ instructions (Invitrogen), with quality assessments conducted on an Agilent 2100 Bioanalyzer. Libraries were constructed using the TruSeq Stranded mRNA Sample Preparation Kit (Illumina) and sequenced on an Illumina HiSeq 2500 platform using a 100-bp paired-end sequencing strategy. The mean number of reads was 134 million, with a mean of 125 million uniquely mapped reads. RNA-seq data analysis was performed as previously described .
Paired-end RNA-seq of experimental cell model HEK293T were preprocessed as described above (hg19). Minimal requirements for an aberrant junction to be included were: SI ≥ 0.1, AQ ≥ 0.2, and CQ ≥ 0.5 in at least one case; junctions with CQ < 0.5 or AQ > 0.4 (not expressed canonical or well-expressed aberrant) in the control groups were excluded. Half-canonical 3′ proximal (n = 786), half-canonical 5′ proximal (n = 412), half-canonical distant (n = 1462), and aberrant exon (n = 760) junctions were characterized by max(SI) in each group (SF3B1K700E, SF3B1WT, SUGP1KD, and siContol). To characterize effect of SUGP1 knockdown and SF3B1K700E overexpression, we used relative shift in maximal splice indexes: ∆SImax = (max(SIExp) − max(SIControl))/max(SIControl)).
Fastq files from paired-end RNA-seq of HAP1 isogenic cell lines were mapped on Human genome (hg19) using STAR (v2.5.3a). BAM files were mined with rMATS tools to detect all alternative splicing events. Junction with False Discovery Rate below 0.01 and |log2(SIMut/SIWT)| higher than 1 were selected as differentially expressed between WT and SUGP1P636L samples.
Cell culture and transfection
HEK293T and HAP1 cell lines were cultured in DMEM supplemented with 10% fetal bovine serum. A point mutation in SUGP1 resulting in P636L amino-acid substitution was introduced using CRISPR/cas9-stimulated homology-directed repair to generate isogenic HAP1 cell lines. A second point mutation in ATP1A1 was simultaneously introduced conferring ouabain resistance . Cells were transfected with preformed Cas9 ribonucleoprotein complexes (RNPs) containing synthetic crRNAs specific for ATP1A1 and SUGP1 along with ssODNs-specified mutation at a 3:1 ratio (Integrated DNA Technologies, Inc, IDT). Sequence of gRNA: TGGTACGCATGTCCTCCTGG; donor sequence: TCCTACCACCACCCTCTCCTGTCGACTGAGCAAAGGCAGCCCAGGAGGACATGCGTACCAGGAGGTTGGGCCGGAAGCGGTAGGCCAGCATCATCCTCTTGCGGAACGCCTCATACTCGTCGTCCTCC. Cells were selected and expanded in the presence of ouabain (0.5 µM) and verified by Sanger sequencing.
Plasmid transfections were carried out in cell lines using 500 ng of plasmid construct and Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s instructions. For siRNA-mediated knockdown, cells were transfected with 50 nM of siRNA using lipofectamine RNAiMAX (Invitrogen) and the following siRNA: siSUGP1 (Cat.No. s33721, Ambion; and GeneSolution Cat.No. 1027416, Qiagen), or control siRNA (Cat.No. S103650318). Total RNA was extracted with NucleoSpin RNA kit (Macherey-Nagel). The quantity and quality of RNA was determined by spectrophotometry (NanoDrop Technologies). Five hundred nanograms of RNA was used as a template for cDNA synthesis with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Twenty-five nanograms of the synthesized cDNA was used as a template for RT–PCR amplification with specific primers for canonical and cryptic forms of DPH5, DLST and ARMC9 as previously reported .
Expression vectors and minigene constructs
pCDNA3.1-Flag vectors containing wild-type and mutated SUGP1 were synthesized by Genscript Corporation. Wild-type and mutated SF3B1, as well as BP and BP’ mutants of TMEM14C and ENOSF1 constructs were previously described .
Cells were lysed in radioimmunoprecipitation assay buffer, and proteins were quantified using a BCA Protein Assay (Pierce). Equal amounts were separated on SDS–polyacrylamide gel electrophoresis gels. Proteins were transferred to nitrocellulose membranes followed by immunoblotting with specific primary antibodies for SUGP1 (1:1,000; HPA004890, Sigma), Flag (1:1,000, #3165; Sigma), and β-actin (1:2,000; #5313; Sigma). The membrane was then incubated at room temperature for 1 h with either goat anti-rabbit or goat anti-mouse Odyssey secondary antibodies coupled to a 700 or 800 nm. Immunolabelled proteins were detected using the Odyssey Infrared Imaging System (Li-cor).
Sequencing data are available as GSE159304.
Obeng EA, Stewart C, Abdel-Wahab O. Altered RNA processing in cancer pathogenesis and therapy. Cancer Discov. 2019;9:1493–510.
Plaschka C, Lin PC, Charenton C, Nagai K. Prespliceosome structure provides insights into spliceosome assembly and regulation. Nature. 2018;559:419–22.
Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365:1384–95.
Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64–9.
Alsafadi S, Houy A, Battistella A, Popova T, Wassef M, Henry E, et al. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat Commun. 2016;7:10615.
Darman RB, Seiler M, Agrawal AA, Lim KH, Peng S, Aird D, et al. Cancer-associated SF3B1 hotspot mutations induce cryptic 3’ splice site selection through use of a different branch point. Cell Rep. 2015;13:1033–45.
Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365:2497–506.
Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2011;44:47–52.
Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 2013;3:1122–9.
Harbour JW, Roberson ED, Anbunathan H, Onken MD, Worley LA, Bowcock AM. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet. 2013;45:133–5.
Martin M, Masshofer L, Temming P, Rahmann S, Metz C, Bornfeld N, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet. 2013;45:933–6.
Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150:1107–20.
Maguire SL, Leonidou A, Wai P, Marchio C, Ng CK, Sapino A, et al. SF3B1 mutations constitute a novel therapeutic target in breast cancer. J Pathol. 2015;235:571–80.
Kong Y, Krauthammer M, Halaban R. Rare SF3B1 R625 mutations in cutaneous melanoma. Melanoma Res. 2014;24:332–4.
Suzuki H, Kumar SA, Shuai S, Diaz-Navarro A, Gutierrez-Fernandez A, De Antonellis P, et al. Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. Nature. 2019;574:707–11.
Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, et al. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep. 2018;23:282–96.e284.
Will CL, Luhrmann R. Spliceosome structure and function. Cold Spring Harb Perspect Biol. 2011;3:a003707.
van der Feltz C, Hoskins AA. Structural and functional modularity of the U2 snRNP in pre-mRNA splicing. Crit Rev Biochem Mol Biol. 2019;54:443–65.
Kahles A, Lehmann KV, Toussaint NC, Huser M, Stark SG, Sachsenberg T, et al. Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell. 2018;34:211–24.e216.
Cretu C, Schmitzova J, Ponce-Salvatierra A, Dybkov O, De Laurentiis EI, Sharma K, et al. Molecular architecture of SF3b and structural consequences of its cancer-related mutations. Mol Cell. 2016;64:307–19.
DeBoever C, Ghia EM, Shepard PJ, Rassenti L, Barrett CL, Jepsen K, et al. Transcriptome sequencing reveals potential mechanism of cryptic 3’ splice site selection in SF3B1-mutated cancers. PLoS Comput Biol. 2015;11:e1004105.
Zhang J, Ali AM, Lieu YK, Liu Z, Gao J, Rabadan R. Disease-causing mutations in SF3B1 alter splicing by disrupting interaction with SUGP1. Mol Cell. 2019;76:82–95.
Lau JW, Lehnert E, Sethi A, Malhotra R, Kaushik G, Onder Z, et al. The cancer genomics cloud: collaborative, reproducible, and democratized—a new paradigm in large-scale computational research. Cancer Res. 2017;77:e3–6.
Dehghannasiri R, Freeman DE, Jordanski M, Hsieh GL, Damljanovic A, Lehnert E, et al. Improved detection of gene fusions by applying statistical methods reveals oncogenic RNA cancer drivers. Proc Natl Acad Sci USA. 2019;116:15524–33.
Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29:24–6.
Dvinge H, Kim E, Abdel-Wahab O, Bradley RK. RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer. 2016;16:413–30.
Ilagan JO, Ramakrishnan A, Hayes B, Murphy ME, Zebari AS, Bradley P, et al. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 2015;25:14–26.
Sampson ND, Hewitt JE. SF4 and SFRS14, two related putative splicing factors on human chromosome 19p13.11. Gene. 2003;305:91–100.
Agafonov DE, Deckert J, Wolf E, Odenwalder P, Bessonov S, Will CL, et al. Semiquantitative proteomic analysis of the human spliceosome via a novel two-dimensional gel electrophoresis method. Mol Cell Biol. 2011;31:2667–82.
Liu Z, Yoshimi A, Wang J, Cho H, Chun-Wei Lee S, Ki M, et al. Mutations in the RNA Splicing Factor SF3B1 promote tumorigenesis through MYC stabilization. Cancer Discov. 2020;10:806–21.
Inoue D, Chew GL, Liu B, Michel BC, Pangallo J, D’Avino AR, et al. Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature. 2019;574:432–6.
Liu Z, Zhang J, Sun Y, Perea-Chamblee TE, Manley JL, Rabadan R. Pan-cancer analysis identifies mutations in SUGP1 that recapitulate mutant SF3B1 splicing dysregulation. Proc Natl Acad Sci USA. 2020;117:10305–12.
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25:2078–9.
Bryant DW Jr, Shen R, Priest HD, Wong WK, Mockler TC. Supersplat−spliced RNA-seq alignment. Bioinformatics. 2010;26:1500–5.
Popova T, Manie E, Stoppa-Lyonnet D, Rigaill G, Barillot E, Stern MH. Genome alteration print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. Genome Biol. 2009;10:R128.
Agudelo D, Duringer A, Bozoyan L, Huard CC, Carter S, Loehr J, et al. Marker-free coselection for CRISPR-driven genome editing in human cells. Nat Methods. 2017;14:615–20.
The translational group of UM at Institut Curie is supported by SIRIC Curie (Grant INCa-DGOSInserm_12554) and the European Union’s Horizon 2020 project “UM Cure 2020” (grant no. 667787). This work benefits also from financial support of the Ligue Nationale Contre le Cancer (Labellisation) and a grant from Canceropole Emergence from Canceropole Ile-de-France (EMERG-1 2017 ImmunSplice). The Seven Bridges Cancer Genomics Cloud has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, contract no. HHSN261201400008C and ID/IQ agreement no. 17 × 146 under contract no. HHSN261201500003I.
Conflict of interest
AH and MHS are inventors of a patent pending related to SUGP1 and SF3B1 mutations effects. EL was employed by Seven Bridges Genomics. Other authors declare no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Alsafadi, S., Dayot, S., Tarin, M. et al. Genetic alterations of SUGP1 mimic mutant-SF3B1 splice pattern in lung adenocarcinoma and other cancers. Oncogene 40, 85–96 (2021). https://doi.org/10.1038/s41388-020-01507-5